KR20240167633A - 종양 치료용 약학 조성물 - Google Patents

종양 치료용 약학 조성물 Download PDF

Info

Publication number
KR20240167633A
KR20240167633A KR1020247029099A KR20247029099A KR20240167633A KR 20240167633 A KR20240167633 A KR 20240167633A KR 1020247029099 A KR1020247029099 A KR 1020247029099A KR 20247029099 A KR20247029099 A KR 20247029099A KR 20240167633 A KR20240167633 A KR 20240167633A
Authority
KR
South Korea
Prior art keywords
cancer
inhibitor
kras
pharmaceutical composition
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247029099A
Other languages
English (en)
Korean (ko)
Inventor
유 가토
마사히코 구메
유사쿠 호리
유스케 아다치
Original Assignee
에자이 알앤드디 매니지먼트 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에자이 알앤드디 매니지먼트 가부시키가이샤 filed Critical 에자이 알앤드디 매니지먼트 가부시키가이샤
Publication of KR20240167633A publication Critical patent/KR20240167633A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020247029099A 2022-03-31 2023-03-29 종양 치료용 약학 조성물 Pending KR20240167633A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JPJP-P-2022-060715 2022-03-31
JP2022060715 2022-03-31
PCT/JP2023/012957 WO2023190748A1 (ja) 2022-03-31 2023-03-29 腫瘍治療用医薬組成物

Publications (1)

Publication Number Publication Date
KR20240167633A true KR20240167633A (ko) 2024-11-27

Family

ID=88202666

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247029099A Pending KR20240167633A (ko) 2022-03-31 2023-03-29 종양 치료용 약학 조성물

Country Status (9)

Country Link
US (1) US20250177406A1 (https=)
EP (1) EP4473970A4 (https=)
JP (1) JPWO2023190748A1 (https=)
KR (1) KR20240167633A (https=)
CN (1) CN118785911A (https=)
AU (1) AU2023246216A1 (https=)
CA (1) CA3244999A1 (https=)
MX (1) MX2024010728A (https=)
WO (1) WO2023190748A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4056580A4 (en) 2019-11-07 2023-12-06 Chugai Seiyaku Kabushiki Kaisha METHOD FOR PRODUCING A PEPTIDE COMPOUND COMPRISING A STERICALLY HINDERED AMINO ACID
BR112022007535A2 (pt) 2019-11-07 2022-07-12 Chugai Pharmaceutical Co Ltd Composto peptídico cíclico tendo ação inibitória de kras
US12312379B2 (en) 2021-05-07 2025-05-27 Chugai Seiyaku Kabushiki Kaisha Methods for producing cyclic compounds comprising N-substituted amino acid residues
KR20250085767A (ko) 2022-09-29 2025-06-12 광조우 조요 파마테크 컴퍼니 리미티드 거대고리 유도체 및 이의 적용
AU2024241633A1 (en) 2023-03-30 2025-11-06 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof
TW202508595A (zh) 2023-05-04 2025-03-01 美商銳新醫藥公司 用於ｒａｓ相關疾病或病症之組合療法
TW202510852A (zh) * 2023-07-20 2025-03-16 日商中外製藥股份有限公司 用於癌症之治療或預防的藥物
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
TW202547461A (zh) 2024-05-17 2025-12-16 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015098853A1 (ja) 2013-12-25 2015-07-02 エーザイ・アール・アンド・ディー・マネジメント株式会社 （６Ｓ，９ａＳ）－Ｎ－ベンジル－６－［（４－ヒドロキシフェニル）メチル］－４，７－ジオキソ－８－（｛６－［３－（ピペラジン－１－イル）アゼチジン－１－イル］ピリジン－２－イル｝メチル）－２－（プロプ－２－エン－１－イル）－オクタヒドロ－１Ｈ－ピラジノ［２，１－ｃ］［１，２，４］トリアジン－１－カルボキサミド化合物
WO2016208576A1 (ja) 2015-06-23 2016-12-29 エーザイ・アール・アンド・ディー・マネジメント株式会社 （６Ｓ，９ａＳ）－Ｎ－ベンジル－６－［（４－ヒドロキシフェニル）メチル］－４，７－ジオキソ－８－（｛６－［３－（ピペラジン－１－イル）アゼチジン－１－イル］ピリジン－２－イル｝メチル）－２－（プロプ－２－エン－１－イル）－オクタヒドロ－１Ｈ－ピラジノ［２，１－ｃ］［１，２，４］トリアジン－１－カルボキサミド化合物の結晶

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL107587A (en) 1993-11-12 1998-08-16 Univ Ramot Farnesyl geranyl or geranyl-geranyl derivatives pharmaceutical compositions containing them and methods for their preparation
AU2004206046B2 (en) 2003-01-21 2009-12-17 Thallion Pharmaceuticals Inc. Farnesyl dibenzodiazepinones, processes for their production and their use as pharmaceuticals
JO3805B1 (ar) 2013-10-10 2021-01-31 Araxes Pharma Llc مثبطات كراس جي12سي
MX373231B (es) * 2015-06-16 2020-05-08 Eisai R&D Man Co Ltd Agente anticancerigeno.
US9861623B1 (en) 2016-10-28 2018-01-09 Macau University Of Science And Technology Combination treatment of RAS-positive diseases with PDE-δ inhibitor and direct autophagy inhibitor
EP3558979B1 (en) 2016-12-22 2021-02-17 Boehringer Ingelheim International GmbH Novel benzylamino substituted quinazolines and derivatives as sos1 inhibitors
AU2018273356B2 (en) 2017-05-22 2021-09-16 Amgen Inc. KRAS G12C inhibitors and methods of using the same
LT3710439T (lt) 2017-11-15 2023-05-10 Mirati Therapeutics, Inc. Kras g12c inhibitoriai
PE20260440A1 (es) 2018-11-09 2026-02-19 Hoffmann La Roche Compuestos de anillo fusionado
WO2020173935A1 (en) 2019-02-26 2020-09-03 Boehringer Ingelheim International Gmbh New isoindolinone substituted indoles and derivatives as ras inhibitors
CN114437065A (zh) 2019-05-21 2022-05-06 益方生物科技(上海)股份有限公司 杂环化合物，其制备方法和用途
MX2022002465A (es) 2019-08-29 2022-05-19 Mirati Therapeutics Inc Inhibidores de kras g12d.
WO2021120890A1 (en) 2019-12-20 2021-06-24 Novartis Ag Pyrazolyl derivatives useful as anti-cancer agents
WO2022031952A2 (en) * 2020-08-07 2022-02-10 City Of Hope Treatments for cancers having kras mutations

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015098853A1 (ja) 2013-12-25 2015-07-02 エーザイ・アール・アンド・ディー・マネジメント株式会社 （６Ｓ，９ａＳ）－Ｎ－ベンジル－６－［（４－ヒドロキシフェニル）メチル］－４，７－ジオキソ－８－（｛６－［３－（ピペラジン－１－イル）アゼチジン－１－イル］ピリジン－２－イル｝メチル）－２－（プロプ－２－エン－１－イル）－オクタヒドロ－１Ｈ－ピラジノ［２，１－ｃ］［１，２，４］トリアジン－１－カルボキサミド化合物
WO2016208576A1 (ja) 2015-06-23 2016-12-29 エーザイ・アール・アンド・ディー・マネジメント株式会社 （６Ｓ，９ａＳ）－Ｎ－ベンジル－６－［（４－ヒドロキシフェニル）メチル］－４，７－ジオキソ－８－（｛６－［３－（ピペラジン－１－イル）アゼチジン－１－イル］ピリジン－２－イル｝メチル）－２－（プロプ－２－エン－１－イル）－オクタヒドロ－１Ｈ－ピラジノ［２，１－ｃ］［１，２，４］トリアジン－１－カルボキサミド化合物の結晶

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
비특허문헌 1: Santos et al., Structural and functional properties of ras proteins, FASEB J. 1989, 3(10), 2151-2163
비특허문헌 2: Interaction between Wnt/β-catenin and RAS-ERK pathways and an anti-cancer strategy via degradations of β-catenin and RAS by targeting the Wnt/β-catenin pathway. npj Precision Onc 2, 5 (2018)
비특허문헌 3: Fodde, et al., Wnt/β-catenin signaling in cancer stemness and malignant behavior, Current Opinion in Cell Biology 2007, 19:150-158

Also Published As

Publication number Publication date
US20250177406A1 (en) 2025-06-05
JPWO2023190748A1 (https=) 2023-10-05
EP4473970A4 (en) 2026-01-21
CA3244999A1 (en) 2025-06-13
CN118785911A (zh) 2024-10-15
MX2024010728A (es) 2024-09-10
EP4473970A1 (en) 2024-12-11
AU2023246216A1 (en) 2024-09-19
WO2023190748A1 (ja) 2023-10-05

Similar Documents

Publication Publication Date Title
KR20240167633A (ko) 종양 치료용 약학 조성물
JP7624985B2 (ja) Ｐｒｍｔ５阻害剤の組合せ医薬
WO2025067459A2 (en) Therapies for the treatment of cancer
JP6855243B2 (ja) 癌治療のためのアピリモド（ａｐｉｌｉｍｏｄ）組成物
WO2022221227A9 (en) Amino-substituted heterocycles for treating cancers with egfr mutations
AU2014372166A1 (en) Pharmaceutical combinations
US20240343728A1 (en) Compounds that inhibit pi3k isoform alpha and methods for treating cancer
TW202132299A (zh) 組合
US20250235426A1 (en) Pharmaceutical Combination and Use Thereof
CN116261455B (zh) 一种药物组合物及其在治疗癌症中的用途
WO2021222147A1 (en) Heterocyclic gcn2 modulators
US8299081B2 (en) Methods for treating drug resistant cancer
CA3213359A1 (en) Alk-5 inhibitors and uses thereof
KR20210005182A (ko) 암 치료를 위한 조합
KR20250166103A (ko) 종양 치료용 약제학적 조성물
KR20140032586A (ko) Ｐｔｅｎ 기능저하에 의한 ｅｇｆｒ-ｔｋｉ 저해제-내성 폐암의 방사선 치료용 약학 조성물
RU2445960C2 (ru) Применение производных пиримидиламинобензамида для лечения системного мастоцитоза
TW202135814A (zh) 組合
WO2019176985A1 (ja) 抗腫瘍剤、抗腫瘍効果増強剤及び抗腫瘍用キット
HK40095032A (zh) 一种药物组合物及其在治疗癌症中的用途
HK40095032B (zh) 一种药物组合物及其在治疗癌症中的用途
EP4724151A1 (en) A 1,5-dihydro-4h-pyrrolo[3,2-c] pyridin-4-one for use in the treatment of cancer
HK40107546A (zh) 抑制PI3K同工型α的化合物和用於治疗癌症的方法
EA049995B1 (ru) Соединения, ингибирующие изоформу альфа pi3k, и способы лечения онкологического заболевания
CN117500803A (zh) 用于治疗具egfr突变的癌症的氨基取代杂环

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20240829

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application